NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Global Cancer Biomarker Market -2019-2026

出版商 DataM Intelligence 商品編碼 745288
出版日期 內容資訊 英文
商品交期: 約2個工作天內
癌症生物標記的全球市場分析 Global Cancer Biomarker Market -2019-2026
出版日期: 2020年01月01日內容資訊: 英文

本報告提供全球癌症生物標記的市場相關分析,彙整市場基本結構和最新形勢,整體市場趨勢預測 (今後8年份),各市場區隔 (生物標記/簡介各技術/各用途) 及地區別詳細趨勢,主要的推動及阻礙市場要素,市場佔有率結構,主要企業的簡介等相關調查。

第1章 分析方法·範圍

第2章 產業分析

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析

第3章 市場概要

  • 流行病學的分析
  • 臨床實驗分析

第4章 產品平台分析

第5章 癌症的不同症狀的市場區隔

  • 肉瘤
  • 大腸癌
  • 子宮頸癌
  • 肺癌
  • 乳癌

第6章 生物標記類別的市場區隔

  • 蛋白質生物標記
  • 遺傳基因生物標記
  • 其他

第7章 簡介各技術的市場區隔

  • 體學技術
  • 細胞遺傳學
  • 免疫測量 (免疫分析法)
  • 影像技術
  • 生物資訊學

第8章 各用途的市場區隔

  • 藥物研發·藥物開發
  • 疾病體檢·診斷
  • 訓練籌劃與風險評估
  • 其他

第9章 各地區的市場區隔

  • 北美 (美國,加拿大,墨西哥等)
  • 歐洲 (英國,德國,西班牙,法國等)
  • 亞太地區 (中國,日本,印度,澳洲等)
  • 南美 (巴西,阿根廷等)
  • 其他的國家 (RoW)

第10章 競爭環境

  • 市場參與企業
  • 主要企業採用的主要策略

第11章 企業簡介

  • AbbVie
  • Boehringer Ingelheim
  • Sanofi
  • Pfizer
  • Merck
  • GSK
  • Roche
  • Johnson and Johnson
  • AstraZeneca
  • Teva Pharmaceutical Industries

第12章 附錄



The global cancer biomarker market is estimated to reach a market value of USD XX billion by 2026 from an initial market value of USD 11,479.2 million in 2018. The global cancer biomarker market is forecasted to grow at a CAGR of 6.34% in the forecasted period 2019-2026.

Increasing Incidence and Cancer Prevalent Pool, Growth in Importance of Biological and Targeted Therapies, Increasing Use in Drug Development, increasing strategic alliances between the companies for the development of cancer biomarker, and growing patient awareness campaigns and programs by government, companies, and NGO's are some of the key trends in the cancer biomarker market.

Market Dynamics

According to Globocan 2012, the incidence rates of cancer types is increasing notably for many cancer types globally. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. Mortality rate of cancers is likely to increase at a higher rate compared to incidence rate during 2015-2030, at a CAGR of 2.6%. By cancer type, incidence population of lung cancer is expected to grow at a faster pace. In terms of mortality too, lung cancers have highest mortality rate, approximately one-fifth of the cancer-related deaths worldwide is due to lung cancers.

Segmentation by Biomarker Type

By biomarker type, genetic biomarker account for the largest share in the cancer biomarker market. The biomarker market is estimated to grow at nominal of pace in the forecasted period growing at a CAGR of XX% in the forecasted period 2019-2026. Genetic Biomarker is defined as a DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention.

Genetic mutations are the primary causes for several cancer types and thus identifying these key mutations holds significant clinical importance in drug development, cancer diagnosis and treatment.

The approval of novel gene based assays and companion diagnostics will fuel the market for genetic biomarkers in the forecast period. For instance, in January 2018, FDA has approved a PMA supplement extending the indications for use of QIAGEN's therascreen EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim's targeted therapy GILOTRIF for first-line treatment of NSCLC.

Segmentation by Geography

North America accounts for the largest market share in the 2017 with the market being dominated by the United States. North America is dominating the cancer biomarkers market due to established R&D infrastructure and high acceptance of biomarker-based cancer testing, adequate reimbursement coverage in this region. In addition, the largest share of North America is due to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, high adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. The US holds the largest market share in North America followed by Canada due to growing research and developments in cancer biomarkers with rising number of cancer cases in this region.

On 5 December 2017, the European Cancer Patient Coalition (ECPC), in collaboration with the Member of the European Parliament Marlene Mizzi (S&D, Malta) organized an event on the topic of Cancer Biomarkers in the Era of Personalized Medicines. The European Medicines Agency has endorsed a UK-US project to use an imaging biomarker to help select Parkinson's disease patients most likely to benefit from clinical trials.

India, China, Brazil, and Australia market are growing at a higher rate while United States, Italy, Germany, Japan, and Spain market are growing at a slower rate but contribute to the largest market revenue in 2017.

Competitive Landscape

The cancer biomarker market is a highly competitive market with genetic biomarker being consolidated market while protein biomarker market being fragmented market. Companies in the industry are focusing on launching novel products into the market with partnerships being the most adopted strategy by the major companies in the industry.

Scope of the Report

Segmentation by Cancer Indication

Hematology malignancies

Prostate cancer


Colorectal Cancer

Cervical Cancer

Lung Cancer

Breast Cancer

Segmentation by Biomarker Type

Protein Biomarker

Generic Biomarker


Segmentation by Profiling Technologies

Omics Technologies



Imaging Technologies


Segmentation by Application

Drug Discovery And Development

Disease Screening and Diagnosis

Treatment Planning & Risk Assessment


The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Why Purchase the Report?

  • Visualize the composition of the global cancer biomarker market with clear distinction between each biomarker and its application
  • Identify commercial opportunities in the global cancer biomarker market analysing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global cancer biomarker market
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1: Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Scope of the report

2: Industry Analysis

  • 2.1 Market Drivers
  • 2.2 Market Restraints
  • 2.3 Porters Five Forces

3. Market Overview

  • 3.1 Epidemiology Analysis
  • 3.2 Clinical Trial Analysis

4. Product Pipeline Analysis

5. Segmentation by Cancer Indication

  • 5.1 Sarcoma
  • 5.2 Colorectal Cancer
  • 5.3 Cervical Cancer
  • 5.4 Lung Cancer
  • 5.5 Breast Cancer

6. Segmentation by Biomarker Type

  • 6.1 Protein Biomarkers
  • 6.2 Genetic Biomarkers
  • 6.3 Others

7. Segmentation by Profiling Technology

  • 7.1 Omics Technologies
  • 7.2 Cytogenetics
  • 7.3 Immunoassays
  • 7.4 Imaging Technologies
  • 7.5 Bioinformatics

8. Segmentation by Application

  • 8.1 Drug Discovery And Development
  • 8.2 Disease Screening and Diagnosis
  • 8.3 Treatment Planning & Risk Assessment
  • 8.4 Others

9. Segmentation by Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
    • 9.1.4 Rest of North America
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 Spain
    • 9.2.4 France
    • 9.2.5 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Rest of the World

10. Competitive Landscape

  • 10.1 Market Player Analysis
  • 10.2 Key Strategies Adopted by Major companies

11. Company Profiles

  • 11.1 AbbVie
  • 11.2 Boehringer Ingelheim
  • 11.3 Sanofi
  • 11.4 Pfizer
  • 11.5 Merck
  • 11.6 GSK
  • 11.7 Roche
  • 11.8 Johnson and Johnson
  • 11.9 AstraZeneca
  • 11.10 Teva Pharmaceutical Industries

12. Appendix

  • 12.1 Disclaimer
  • 12.2 Contact Us